Video

Utility of Trapelo to Increase Molecular Testing Rates

Author(s):

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Lori Brisbin, vice president of precision medicine at Texas Oncology, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Trapelo is a decision support tool that assists in choosing the best test for patients based on their tumor type, explains Brisbin. The tool is updated every day with guidelines from the National Comprehensive Cancer Network, ASCO, and the FDA. People can also input information on clinical trials to help identify eligible patients, according to Brisbin.

The purpose of Trapelo is to increase the number of patients who receive molecular testing because, currently, only 30% of patients are receiving molecular testing, says Brisbin. This tool will advise which patients to test because each disease has different standards. For example, patients with breast cancer typically receive testing throughout the disease course, but patients with lung cancer are tested during stage III and metastatic stage IV disease. Community oncologists who work with several different tumor types struggle to keep track of information regarding testing for each disease, but Trapelo should offer a quick way to check the most up-to-date guidelines, concludes Brisbin.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD